RT Journal Article
SR Electronic
T1 Circulating SDF4 as a Potential Early Detection Biomarker for Pancreatic Cancer
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2025.08.13.25333571
DO 10.1101/2025.08.13.25333571
A1 Kageyama, Itsuki
A1 Lin, Yingsong
A1 Sasahira, Naoki
A1 Ozaka, Masato
A1 Sasaki, Takashi
A1 Ueno, Makoto
A1 Ishii, Hiroshi
A1 Egawa, Naoto
A1 Adachi, Yasushi
A1 Sasakabe, Tae
A1 Kawai, Sayo
A1 Nakatochi, Masahiro
A1 Yamada, Hiroya
A1 Kanda, Mitsuro
A1 Kikuchi, Shogo
A1 Hishida, Asahi
YR 2025
UL http://medrxiv.org/content/early/2025/08/16/2025.08.13.25333571.abstract
AB Pancreatic cancer is a highly aggressive malignancy that is often diagnosed at an advanced stage, largely due to the lack of reliable biomarkers for early detection. Stromal cell–derived factor 4 (SDF4), also known as Cab45, is a secreted calcium-binding protein localized to the Golgi apparatus, and has been implicated in various tumor types. However, its clinical relevance in pancreatic cancer remains poorly understood. In this study, we investigated the diagnostic potential of circulating SDF4 levels using data from a hospital-based case–control study in Japan, consisting of 124 patients with pancreatic cancer (stage I–IV) and 125 age- and sex-matched controls. Plasma SDF4 concentrations were measured using an enzyme-linked immunosorbent assay (ELISA). SDF4 levels were significantly elevated in pancreatic cancer patients across all stages compared with controls (p < 0.001). Notably, patients with early-stage diseases (stage I and II) already exhibited substantial increases. Receiver operating characteristic analysis yielded an area under the curve (AUC) of 0.82 for all stages and 0.81 for early-stage patients, indicating good discriminatory performance, including in potentially resectable disease. These findings suggest that SDF4 is elevated as a result of tumor-related biological activity and may represent a promising blood-based biomarker for pancreatic cancer. Its elevation across both early and advanced stage supports further investigation of SDF4 as a complementary marker to carbohydrate antigen 19-9 (CA19-9). Validation in prospective cohorts and in combination with other biomarkers will be essential to clarify its clinical utility.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by JSPS KAKENHI Grant Number 23K09646 from the Ministry of Education, Culture, Sports, Science and Technology of Japan.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Ethics Committee of Aichi Medical University School of Medicine (Approval No. 2024-M004).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.